Combined medicine for treating ulcerative colitis and preparation method thereof

Abstract

The invention discloses a combined medicine for treating ulcerative colitis, which comprises the following components according to the dosage ratio: red mulberry AAL with the dosage range of 20-80mg / kg; the dosage of the sodium butyrate NaB ranges from 50 mg / kg to 800 mg / kg; the dosage range of the astragalus polysaccharide APS is between 100 mg / kg and 400 mg / kg. The combined use effect of the three medicines is better than the anti-inflammation and hemostasis effects of the red mulberry, the sodium butyrate and the astragalus polysaccharide which are singly used, the weight of a mouse can be obviously increased, the death rate of the mouse is reduced, the hemafecia condition is relieved, the intestinal tissue inflammation damage and inflammatory cell infiltration are further relieved, and the mRNA expression level of inflammatory factors is reduced, which is not reported by people at present. And a new therapeutic drug choice is provided for treating UC. Compared with the current medicine for clinically treating UC, the medicine selected in the experiment is low in price and easy to popularize and accept.

Description

technical field [0001] The invention relates to the technical field of medicines for treating diseases, and is mainly aimed at ulcerative colitis, in particular to a combined medicine for treating ulcerative colitis and a preparation method thereof. Background technique [0002] Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD), with frequent abdominal pain, diarrhea, and mucus, pus and blood in the stool as the main clinical manifestations, most of which are located in the rectum and sigmoid colon. The main disease feature of UC is persistent and recurrent intestinal mucosal inflammation. Most patients with initial onset have a course of more than 4 weeks. The clinical analysis is mainly based on the results of colonoscopy combined with mucosal biopsy. The lesions of UC are mainly continuous and diffuse congestion and edema of the colonic mucosa, with mucus, pus and blood attached, accompanied by ulcers and erosion. Studies have shown that the number of...

AI Technical Summary

Problems solved by technology

At present, aminosalicylates, corticosteroids, immunomodulatory agents, biological agents, etc. are mostly used in clinical treatment of UC, but the expensive drug prices and high recurrence rate after drug withdrawal limit the clinical value of drugs, even the latest drugs, The remission rate is less than 50%. Finding new therapeutic drugs and exploring the pathogenesis have become urgent problems in the clinical diagnosis and treatment of UC.

Images